Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Valeant Pharmaceuticals International, Inc. (Valeant) is a specialty pharmaceutical company. It carries out the development, manufacture and marketing of a wide range of specialty, over-the-counter (OTC) and generic drugs. The company also offers medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada and the US. Valeant is headquartered in Laval, Quebec, Canada.
Valeant Pharmaceuticals International, Inc. Key Recent Developments
Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors
Jun 27, 2016: Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand For Contact Lens Care
Jun 17, 2016: Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations
Jun 16, 2016: Valeant Pharmaceuticals Announces Launch Of New PreserVision AREDS 2 Formula + Multivitamin
Jun 15, 2016: Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Valeant Pharmaceuticals International, Inc. - Key Facts 6
Valeant Pharmaceuticals International, Inc. - Key Employees 7
Valeant Pharmaceuticals International, Inc. - Key Employee Biographies 8
Valeant Pharmaceuticals International, Inc. - Major Products and Services 9
Valeant Pharmaceuticals International, Inc. - Pharmaceutical Pipeline Products Data 13
Valeant Pharmaceuticals International, Inc., Pipeline Products by Therapy Area 13
Valeant Pharmaceuticals International, Inc., Pipeline Products by Development Phase 14
Valeant Pharmaceuticals International, Inc. - History 17
Valeant Pharmaceuticals International, Inc. - Company Statement 25
Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Section 2 – Company Analysis 37
Valeant Pharmaceuticals International, Inc. - Business Description 37
Valeant Pharmaceuticals International, Inc. - Corporate Strategy 39
Valeant Pharmaceuticals International, Inc. - SWOT Analysis 40
SWOT Analysis - Overview 40
Valeant Pharmaceuticals International, Inc. - Strengths 40
Strength - Core Segment: Pharmaceuticals 40
Strength - Focus on Research & Development Activities 40
Strength - Business Partnerships 40
Valeant Pharmaceuticals International, Inc. - Weaknesses 41
Weakness - Patent Infringement Concerns 41
Weakness - Virazole - Microbial Contamination 41
Weakness - Higher Cost Structure 41
Valeant Pharmaceuticals International, Inc. - Opportunities 42
Opportunity - Global Dermatology Market 42
Opportunity - Product Pipeline 42
Opportunity - Inorganic Growth: Strategic Acquisitions 42
Valeant Pharmaceuticals International, Inc. - Threats 43
Threat - Intense Competition 43
Threat - Stringent Government Regulations 43
Threat - Reliance on Major Customers 43
Valeant Pharmaceuticals International, Inc. - Key Competitors 44
Section 3 – Company Financial Ratios 45
Financial Ratios - Capital Market Ratios 45
Financial Ratios - Annual Ratios 46
Performance Chart 48
Financial Performance 48
Financial Ratios - Interim Ratios 49
Financial Ratios - Ratio Charts 50
Section 4 – Company’s Lifesciences Financial Deals and Alliances 51
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 51
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 52
Valeant Pharmaceuticals International, Inc., Recent Deals Summary 53
Section 5 – Company’s Recent Developments 54
Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 54
Jun 17, 2016: Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations 55
Jun 16, 2016: Valeant Pharmaceuticals Announces Launch Of New PreserVision AREDS 2 Formula + Multivitamin 56
Jun 15, 2016: Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director 57
Jun 07, 2016: Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results 58
May 26, 2016: Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller 60
May 16, 2016: Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel 61
May 16, 2016: Valeant Pharmaceuticals Provides Update on Regulatory Matters 62
May 16, 2016: Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters 63
May 05, 2016: Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs 64
Section 6 – Appendix 65
Methodology 65
Ratio Definitions 65
About GlobalData 69
Contact Us 69
Disclaimer 69
List of Tables
Valeant Pharmaceuticals International, Inc., Key Facts 6
Valeant Pharmaceuticals International, Inc., Key Employees 7
Valeant Pharmaceuticals International, Inc., Key Employee Biographies 8
Valeant Pharmaceuticals International, Inc., Major Products and Services 9
Valeant Pharmaceuticals International, Inc., Number of Pipeline Products by Therapy Area 13
Valeant Pharmaceuticals International, Inc., Number of Pipeline Products by Development Stage 14
Valeant Pharmaceuticals International, Inc., Pipeline Products By Therapy Area and Development Phase 15
Valeant Pharmaceuticals International, Inc., History 17
Valeant Pharmaceuticals International, Inc., Other Locations 28
Valeant Pharmaceuticals International, Inc., Subsidiaries 28
Valeant Pharmaceuticals International, Inc., Key Competitors 44
Valeant Pharmaceuticals International, Inc., Ratios based on current share price 45
Valeant Pharmaceuticals International, Inc., Annual Ratios 46
Valeant Pharmaceuticals International, Inc., Interim Ratios 49
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 51
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 52
Valeant Pharmaceuticals International, Inc., Recent Deals Summary 53
Currency Codes 65
Capital Market Ratios 65
Equity Ratios 66
Profitability Ratios 66
Cost Ratios 67
Liquidity Ratios 67
Leverage Ratios 68
Efficiency Ratios 68
List of Figures
Valeant Pharmaceuticals International, Inc., Pipeline Products by Therapy Area 13
Valeant Pharmaceuticals International, Inc., Pipeline Products by Development Phase 14
Valeant Pharmaceuticals International, Inc., Performance Chart (2011 - 2015) 48
Valeant Pharmaceuticals International, Inc., Ratio Charts 50
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 51
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 52
